Absence Of Pediatric Plans Put NDAs/BLAs At Risk For Refusal To File
Executive Summary
FDA may refuse to file drug applications that do not include a pediatric plan when sponsors ask for a deferral of pediatric data until after a drug is approved.
You may also be interested in...
Pediatric Study Plans Would Be Required At End Of Phase II Under Bipartisan House Bill
Rather than assessing monetary penalties for violating study deadlines, H.R. 4274 directs FDA to issue warning letters and publish them on its website.
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
The regular reauthorization of PREA and BPCA, when coupled with the long review horizon for pediatric studies at FDA, could be hindering sponsors’ willingness to conduct the trials, according to a Government Accountability Office Report.
Reauthorizations Cause Sponsor Angst For PREA, BPCA Studies, GAO Finds
The regular reauthorization of PREA and BPCA, when coupled with the long review horizon for pediatric studies at FDA, could be hindering sponsors’ willingness to conduct the trials, according to a Government Accountability Office Report.